Kyverna Therapeutics (KYTX) Competitors $4.00 +0.13 (+3.36%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends KYTX vs. ERAS, CRON, EOLS, DNTH, RAPP, AUTL, CGEM, OCS, PRTA, and TRDAShould you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Erasca (ERAS), Cronos Group (CRON), Evolus (EOLS), Dianthus Therapeutics (DNTH), Rapport Therapeutics (RAPP), Autolus Therapeutics (AUTL), Cullinan Therapeutics (CGEM), Oculis (OCS), Prothena (PRTA), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry. Kyverna Therapeutics vs. Erasca Cronos Group Evolus Dianthus Therapeutics Rapport Therapeutics Autolus Therapeutics Cullinan Therapeutics Oculis Prothena Entrada Therapeutics Kyverna Therapeutics (NASDAQ:KYTX) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and community ranking. Is KYTX or ERAS more profitable? Erasca's return on equity of -42.26% beat Kyverna Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kyverna TherapeuticsN/A -51.12% -37.91% Erasca N/A -42.26%-34.97% Do analysts rate KYTX or ERAS? Kyverna Therapeutics currently has a consensus target price of $25.71, indicating a potential upside of 542.86%. Erasca has a consensus target price of $5.90, indicating a potential upside of 132.28%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Kyverna Therapeutics is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyverna Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Erasca 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Do institutionals & insiders hold more shares of KYTX or ERAS? 18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 21.5% of Erasca shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media refer more to KYTX or ERAS? In the previous week, Kyverna Therapeutics had 37 more articles in the media than Erasca. MarketBeat recorded 39 mentions for Kyverna Therapeutics and 2 mentions for Erasca. Erasca's average media sentiment score of 1.15 beat Kyverna Therapeutics' score of 0.09 indicating that Erasca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 31 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, KYTX or ERAS? Kyverna Therapeutics has higher revenue and earnings than Erasca. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKyverna Therapeutics$7.03M24.56-$60.37MN/AN/AErascaN/AN/A-$125.04M-$0.83-3.06 Does the MarketBeat Community believe in KYTX or ERAS? Erasca received 14 more outperform votes than Kyverna Therapeutics when rated by MarketBeat users. Likewise, 70.59% of users gave Erasca an outperform vote while only 66.67% of users gave Kyverna Therapeutics an outperform vote. CompanyUnderperformOutperformKyverna TherapeuticsOutperform Votes1066.67% Underperform Votes533.33% ErascaOutperform Votes2470.59% Underperform Votes1029.41% SummaryKyverna Therapeutics and Erasca tied by winning 7 of the 14 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.>> Register for the Workshop Now Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYTX vs. The Competition Export to ExcelMetricKyverna TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$172.69M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E RatioN/A46.7391.3417.19Price / Sales24.56411.851,116.63116.80Price / CashN/A182.1042.5837.86Price / BookN/A3.894.794.78Net Income-$60.37M-$42.21M$120.07M$225.60M7 Day Performance-9.50%-2.14%-1.90%-1.24%1 Month Performance0.25%4.21%11.43%3.06%1 Year PerformanceN/A18.40%30.59%16.50% Kyverna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYTXKyverna Therapeutics2.4272 of 5 stars$4.00+3.4%$25.71+542.9%N/A$172.69M$7.03M0.0096News CoverageHigh Trading VolumeERASErasca2.17 of 5 stars$2.62+2.3%$5.90+125.2%+35.8%$740.75MN/A-3.08126News CoveragePositive NewsGap UpCRONCronos Group1.8381 of 5 stars$1.94+0.3%$3.00+55.0%+4.8%$739.75M$87.24M-15.19356News CoverageEOLSEvolus3.8165 of 5 stars$11.51flat$23.00+99.8%+12.5%$728.81M$202.09M-12.73170DNTHDianthus Therapeutics1.3413 of 5 stars$24.31+2.1%$46.43+91.0%+213.2%$719.58M$2.83M-9.5280Analyst ForecastNews CoverageRAPPRapport Therapeutics1.5333 of 5 stars$19.34+3.0%$35.00+81.0%N/A$707.46MN/A0.00N/AAUTLAutolus Therapeutics2.5563 of 5 stars$2.63+5.6%$10.40+295.4%-58.4%$699.82M$1.70M-2.06330CGEMCullinan Therapeutics1.7981 of 5 stars$11.90+1.3%$31.67+166.1%+32.7%$692.91M$18.94M-4.1430News CoverageOCSOculis1.6512 of 5 stars$17.06-0.2%$29.20+71.2%+57.2%$691.00M$980,000.00-8.852PRTAProthena1.6262 of 5 stars$12.64-1.2%$61.83+389.2%-58.8%$680.15M$133.35M-5.16173Analyst ForecastNews CoverageTRDAEntrada Therapeutics2.8936 of 5 stars$18.14+2.7%$25.67+41.5%+17.3%$678.80M$129.01M11.11110Positive NewsGap Down Related Companies and Tools Related Companies ERAS Alternatives CRON Alternatives EOLS Alternatives DNTH Alternatives RAPP Alternatives AUTL Alternatives CGEM Alternatives OCS Alternatives PRTA Alternatives TRDA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KYTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
